

November 10, 2021	
National Stock Exchange of India Limited,	BSE Limited,
Listing Compliance Department	Listing Department,
Exchange Plaza, C-1, Block G,	Phiroze Jeejeebhoy Towers,
Bandra Kurla Complex,	Dalal Street,
Bandra (East)	Mumbai- 400001
Mumbai – 400 051	
Scrip Symbol: GALAXYSURF	Scrip Code: 540935

Sub: Investor presentation on the Unaudited Financial Results for the quarter & half year ended September 30, 2021.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation on the Unaudited Financial Results for the quarter & half year ended September 30, 2021.

The information is also hosted in announcement section on the website of the Company at <u>www.galaxysurfactants.com</u>.

We request you to take the same on record.

Yours faithfully, For **Galaxy Surfactants Limited**

Niranjan Ketkar Company Secretary M. No. A20002 encl: as above

Communication Address:

Rupa Solitaire, Ground Floor, Unit no. 8, 12A and 14 Millennium Business Park, Mahape, Navi Mumbai, 400 710 Ph: +91-22-33063700

Galaxy Surfactants Limited

Regd. Office: C-49/2, TTC Industrial Area, Pawne, Navi Mumbai-400 703, India CIN: L39877MH1986PLC039877 Ph: +91-22-27616666 Fax : +91-22-27615883/ 27615886 e-mail : galaxy@galaxysurfactants.com Website: www.galaxysurfactants.com





Galaxy Surfactants Limited

Investor Presentation - November 2021

6









This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Galaxy Surfactants Limited.** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.





Q2FY22 Performance Highlights

Q2FY22: Key Developments



Supply Chain Constraints and delays in the availability of critical feedstocks impact Volumes and EBITDA. Adverse impact of Rs. 20 Crores on EBITDA

Across the board inflationary scenario combined with Supply Chain volatility (Month on Month rise in Freight Costs and Container unavailability) impact International Volumes and Margins

India volumes flat YoY due to the high base (pent up demand) in Q2FY21. While YoY and QoQ volumes have remained flat, structurally we are seeing signs of a sustained uptick in volumes


Performance Surfactants report a decline on the back of degrowth in AMET. This is mainly due to the unavailability of a critical feedstock used for manufacturing performance surfactants. For H1 the volumes have degrown by 1%

Specialty Care Products report a decline in Q2FY21 due to supply chain constrains. Overall, for H1 the same has grown at 13%



Volume: Q2FY22 Highlights





India Market grew YoY by 0.1%



Africa Middle East Turkey de-grew YoY by 13.3% Rest of the World de-grew YoY by 7.1%






While Demand remains robust, inability to service the same due to supply side constraints impinged our ability to maximize value



Volume: H1FY22 Highlights










Rest of the World grew by 8.8%





Q2FY22 & H1FY22 Consolidated Highlights





Responsible Care

Consolidated Profit & Loss Statement



Particulars (Rs. In Crores)	Q2FY22	Q2FY21	Y-o-Y	Q1FY22	Q-o-Q	H1FY22	H1FY21	Y-o-Y	FY21
Net Revenue from Operations	877.3	718.7	22.1%	826.4	6.2%	1,703.7	1,325.8	28.5%	2,784.1
Other Income	5.0	4.6		4.5		9.6	5.2		10.9
Total Revenue	882.3	723.3	22.0%	830.9	6.2%	1,713.2	1,331.1	28.7%	2,794.9
Cost of Material Consumed	644.5	457.7		564.2		1,208.7	857.3		1,774.6
Employee's Benefits Expense	47.8	49.8		54.2		102.0	96.1		204.0
Other Expenses	114.2	89.6		99.5		213.7	160.5		356.6
EBITDA	75.9	126.1	-39.8%	113.0	-32.8%	188.9	217.2	-13.0%	459.7
EBITDA Margin	8.6%	17.4%		13.6%		11.0%	16.3%		16.4%
Depreciation	18.1	16.7		16.8		34.9	33.1		74.0
EBIT	57.8	109.4	-47.2%	96.2	-39.9%	154.0	184.1	-16.4%	385.7
Finance cost	3.7	3.2		2.9		6.6	8.0		13.4
PBT	54.1	106.2	-49.0%	93.3	-42.0%	147.4	176.1	-16.3%	372.3
Tax expense	12.2	24.45		16.4		28.6	37.85		70.2
PAT	41.9	81.7	-48.7%	76.8	-45.4%	118.8	138.2	-14.1%	302.1
PAT Margin	4.8%	11.3%		9.2%		6.9%	10.4%		10.8%
Other Comprehensive Income	0.5	-10.6		7.7		8.2	-12.1		-18.8
Total Comprehensive Income	42.4	71.1	-40.3%	84.5	-49.8%	127.0	126.1	0.7%	283.3
EPS	11.83	23.06		21.67		33.5	38.99		85.22

Fatty Alcohol prices in this Quarter increased to an average price of \$ 1,828/MT vs, average prices of \$ 1,228/MT in Q2FY21. The same was \$ 2,069/MT in Q1FY22



Consolidated Balance Sheet



Particulars (Rs. In Crores)	Sep'21	Mar'21
ASSETS		
Property, Plant and Equipment	576.7	591.7
Right-of-use assets	143.1	111.9
Capital work-in-progress	181.4	124.0
Goodwill	2.7	2.7
Other Intangible Assets	5.0	5.7
Financial Assets		
(i) Loans	0.5	0.3
(ii) Other financial assets	9.7	8.9
Deferred Tax Assets (Net)	1.7	0.7
Income Tax Assets (Net)	18.6	11.2
Other Non-current tax assets	41.3	35.0
Total Non-Current Assets	980.8	891.8
Current Assets		
Inventories	490.8	427.8
Financial Assets		
(i) Investments	12.8	43.5
(ii) Trade receivables	558.7	468.9
(iii) Cash and cash equivalents	110.4	81.5
(iv) Bank Balances other than cash and cash equivalents	2.9	29.9
(v) Loans	0.4	0.3
(vi) Other Financial Assets	9.6	5.9
Other Current Assets	105.1	99.9
Total Current Assets	1,290.7	1,157.7
TOTAL ASSETS	2,271.5	2,049.5

Particulars (Rs. In Crores)	Sep'21	Mar'21
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	1,378.7	1,266.0
Total Shareholders Fund	1,414.2	1,301.4
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	93.3	77.4
(ii) Lease Liabilities	47.8	16.9
(iii) Other Financial Liabilities	0.4	0.4
Provisions	9.9	10.1
Deferred Tax Liabilities (Net)	25.5	23.3
Other non-current liabilities	0.0	0.0
Total Non-Current Liabilities	176.8	128.0
Current Liabilities		
Financial Liabilities		
(i) Borrowings	266.5	190.6
(ii) Trade Payables	363.2	377.0
(iii) Lease Liabilities	5.9	4.4
(iv) Other Financial Liabilities	5.5	5.4
Other Current Liabilities	32.1	33.0
Provisions	6.1	8.6
Current Tax Liabilities (Net)	1.2	1.2
Total Current Liabilities	680.5	620.1
TOTAL EQUITY & LIABILITIES	2,271.5	2,049.5



Consolidated Cash Flow



	Half Yea	ar ended
Particulars (Rs. In Crores)	Sep'21	Sep'20
Cash Flow From Operating Activities :		
Profit After Tax	118.8	138.2
Operating Profit before working Capital changes	183.5	213.8
Net cash flows generated from/(used) in Operating Activities (A)	(25.1)	186.1
Net cash flows generated from/(used) in Investing Activities (B)	(13.2)	(41.0)
Net cash flows generated from/(used) in Financing Activities (C)	66.0	(131.0)
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	27.7	14.1
Opening cash and cash equivalents	81.5	47.7
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	1.2	(0.1)
Closing cash and cash equivalents	110.4	61.7



Standalone Profit & Loss Statement



Particulars (Rs. In Crores)	Q2FY22	Q2FY21	Y-o-Y	Q1FY22	Q-o-Q	H1FY22	H1FY21	Y-o-Y	FY21
Net Revenue from Operations	624.7	489.6	27.6%	554.8	12.6%	1,179.5	849.3	38.9%	1,830.5
Other Income	5.7	-1.5		5.8		11.5	0.8		4.4
Total Revenue	630.3	488.1	29.1%	560.6	12.4%	1,190.9	850.1	40.1%	1,834.9
Cost of Material Consumed	479.1	314.6		402.3		881.3	553.5		1,208.1
Employee's Benefits Expense	24.4	25.5		28.9		53.3	49.2		105.7
Other Expenses	75.3	57.7		65.6		140.9	97.7		223.7
EBITDA	51.6	90.4	-42.9%	63.9	-19.2%	115.5	149.7	-22.9%	297.5
EBITDA Margin	8.2%	18.5%		11.4%		9.7%	17.6%		16.2%
Depreciation	10.8	10.7		10.9		21.6	21.0		49.8
EBIT	40.9	79.7	-48.7%	53.0	-22.9%	93.8	128.7	-27.1%	247.7
Finance cost	2.3	1.9		1.9		4.2	5.1		8.4
PBT	38.6	77.8	-50.4%	51.1	-24.4%	89.6	123.7	-27.5%	239.3
Tax expense	9.9	20.0		12.9		22.8	31.7		61.5
PAT	28.7	57.8	-50.4%	38.1	-24.8%	66.8	92.0	-27.4%	177.9
PAT Margin	4.5%	11.8%		6.8%		5.6%	10.8%		9.7%
Other Comprehensive Income	-0.1	0.2		-0.1		-0.1	0.4		-1.2
Total Comprehensive Income	28.6	58.0	-50.6%	38.1	-24.8%	66.7	92.3	-27.8%	176.6
EPS	8.09	16.3		10.75		18.84	25.94		50.17



Standalone Balance Sheet



Particulars (Rs. In Crores)	Sep'21	Mar'21
ASSETS		
Property, Plant and Equipment	348.6	358.5
Right-of-use assets	97.4	99.2
Capital work-in-progress	164.6	116.2
Goodwill		
Other Intangible Assets	4.8	5.6
Financial Assets		
(i) Investments	222.8	216.7
(ii) Loans	0.5	0.3
(iii) Other financial assets	6.4	5.6
Deferred Tax Assets (Net)		
Income Tax Assets (Net)	15.4	8.0
Other Non-current tax assets	28.4	28.6
Total Non-Current Assets	889.0	838.7
Current Assets		
Inventories	293.8	270.2
Financial Assets		
(i) Trade receivables	385.2	339.6
(ii) Cash and cash equivalents	3.4	11.9
(iii) Bank Balances other than cash and cash equivalents	2.2	12.9
(iv) Loans	0.3	0.3
(v) Other Financial Assets	9.6	6.0
Other Current Assets	61.8	78.1
Total Current Assets	756.3	718.9
TOTAL ASSETS	1,645.3	1,557.6

Particulars (Rs. In Crores)	Sep'21	Mar'21
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	1,033.9	981.4
Total Shareholders Fund	1,069.3	1,016.8
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	72.7	53.0
(ii) Lease Liabilities	3.5	4.8
(iii) Other Financial Liabilities	0.4	0.4
Provisions	9.9	10.1
Deferred Tax Liabilities (Net)	32.9	29.3
Other non-current liabilities	0.0	0.0
Total Non-Current Liabilities	119.3	97.5
Current Liabilities		
Financial Liabilities		
(i) Borrowings	127.5	110.8
(ii) Trade Payables	299.0	306.5
(iii) Lease Liabilities	2.8	2.7
(iv) Other Financial Liabilities	4.8	4.0
Other Current Liabilities	16.2	12.8
Provisions	5.2	5.2
Current Tax Liabilities (Net)	1.2	1.2
Total Current Liabilities	456.6	443.2
TOTAL EQUITY & LIABILITIES	1,645.3	1,557.6




Standalone Cash Flow



	Half Yea	ar ended
Particulars (Rs. In Crores)	Sep'21	Sep'20
Cash Flow From Operating Activities :		
Profit After Tax	66.8	92.0
Operating Profit before working Capital changes	107.8	149.1
Net cash flows generated from/(used) in Operating Activities (A)	18.7	133.8
Net cash flows generated from/(used) in Investing Activities (B)	(43.7)	(43.2)
Net cash flows generated from/(used) in Financing Activities (C)	16.6	(90.5)
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	(8.5)	0.1
Opening cash and cash equivalents	11.9	16.9
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	0.0	0.9
Closing cash and cash equivalents	3.4	17.9




Business Overview



Truly Indian MNC...





...Vertically Integrated in HPC Industry









India's Largest Manufacturer of Oleochemical based Surfactants and Speciality Care Products for Home Care and Personal Care Industries (HPC) Consumer to Innovation & Chemistry Technology 05 03 01 02 **Global Supplier** 04 Multiple High Growth to Global Brands Products across Industry Categories



Our growth trajectory over Three Decades




1986: Incorporation of Company 1984: New Plant at Tarapur for Ethoxylates, Phenoxyethanol, Sunscreens	 1994: New plant set up at Tarapur 1995: Acquisition of Galaxy Chemicals 1997: Sulfonation plant Setup at Taloja and Research Centre at Navi Mumbai 1998: Commissioning of new plant in Taloja 	 2004: setting up of EOU at Taloja 2009: Acquisition of Tri-K Industries Galaxy Chemicals Egypt S.A.E. & Rainbow Holdings GmbH became step down subsidiary 1317 322 382 	2011: Commissioning of Egypt and Jhagadia Plants2014: Purchase of business of Surfactants International LLC2016: Expansion of Jhagadia Plant for mild surfactants169616961801	Revenue (Rs in Crores)
1980 1984 1988 1990 1980-1990	1992 1994 1998 2000 20 1990-2000		2014 2016 2019 2010 - 2 0	2020 2021
 IMPORT SUBSTITUTION Established credentials in surfactants/ specialty ingredients space Due to high import duties, personal care products were considered luxury goods Galaxy was a strong supplier for import substitution Developed a solid R&D base 	 INDIA GROWTH PHASE Post Economic Liberalisation, market for personal care products grew substantially Galaxy emerged as a strong player Grew exponentially led by strong innovation capabilities Focused on capturing the domestic market and large customer accounts Set up capacities to cater to the emerging requirements 	 EXPORT GROWTH PHASE Strategic shift with focus on Global markets expansion Made investments to acquire manufacturing facilities at USA, Egypt and established international offices Increased share of revenue from international business 	GLOBAL ESTABLISH Dominant Share in India Increased Global Participations Supplier Recognitions (Global) Strong R&D Capability Customer Partnership IPO – listing of the company on B Accepted as Global Vendo with best Internatio	IMENT SE and NSE or benchmarked



Our focus is Personal & Home Care Segment

Responsible Care®





... with over 210+ Product Offerings



Performance	Anionic Surfactants	 FAES, FAS, LABSA		 Foam and Dirt removal properties
Surfactants	Non-Ionics Surfactants	 Ethoxylates		 Cosmetics and Personal care products as emulsifiers and solubilisers
	- Amphoteric Surfactants	 Betaines		 Dermatological properties to reduces skin irritation
	Cationic Surfactants	 Quats	efits	 Effective conditioning aids: substantively to hair and antimicrobial properties
	UV Filters	 Sunscreen Agents (OMC, OCN &Others)	Consumer Benefits	Absorb or block the harmful radiation, Mild for the skin with Moisturizing
Speciality Care Products	Preservatives, Preservative Blends	Phenoxyethanol, Preservative Blends	Consu	Reduced toxicity & prevent spoilage
	Speciality Ingredients	 Mild Surfactants (MS), Proteins and Syndet & Transparent Bathing Bar Flakes, Surfactant Blends		 MS: Cleanse adequately without compromising basic function of skin Protein: cosmetic industry for conditioning, protection and strengthening of hair/skin, anti-irritancy, moisturization etc
Bifurcation is only for Investor community as	Fatty Alkanolamides (FA) and Fatty Acid Easters (FAE)			FA & FAE: Foam, viscosity boosters and pearlizer in a formulation
every product has different functionality	Other Care Products	 Conditioning Agents, Polyquats & Amine Oxides		 Improves the quality of another material also called as moisturizers, conditioning benefits to the hair etc

Our Business Segments...



Performance Surfactants

"Substantive Raw Material in Customer's End-products"

- Products are functional in nature where Endconsumer require foaming & cleansing
- Large volume consumption in all rinse-off formulations
- Products are Pulled by FMCG as it is required due to impulse buying from end consumer

Speciality Care Products

"Unique Functionality to Customer's End-products"

- Niche & Premium products
- Low volume consumption
- Oligopolistic for most products
- Low penetration due to its unique application





About Product



No. of Products



Revenue Mix (H1FY22)








Our Global Footprints






Presence in High Growth & Matured Markets





"Consumer to Chemistry": Creation of Products





Collaborative product development with Customers which helps Customers in choosing "**Right Technology** with Right Application"

Inhouse R&D Team of 74 professionals comprising of doctorates, chemists and engineers

Well-Equipped R&D Centre, Pilot Plant at Tarapur, Maharashtra; Product applications centre for proteins at Denville, USA


Innovation Funnel (adopted in 2007) to consistently diversify product offerings, meet customer needs and consumer trends





State-of-the-art Manufacturing Facilities






*Environmental clearances for expansion and additional land available at Jhagadia and Suez plants



1400+ Clients across 80+ Countries





Awards & Certifications: Won in the Past Decade





"Great Place to Work" for the Fiscal 2017-2018

"Silver Medal" in India Green Manufacturing Challenge 2016 for Jhagadia unit

"Certificate of Appreciation" in occupational safety & health by National Safety Council of India for Taloja Plant, 2011

"Special Award for TPM Achievement", 2008

"Certificate of Merit 2008 -Manufacturing Category" in the IMC Ramkrishna Bajaj National Quality Award 2008"



Accolades Received in H1FY22











Accolades Received during FY21





Company won Gold medal for their EcoVadis CSR rating Company **received EFfCI GMP certification** for its manufacturing facility located at **Jaghadia**

Certificate of Appreciation For valuable association as a Business Partner a during the Covid-19 crisis

Received **Green Company Silver Certification for** Taloja facility











Mr. Unnathan Shekhar Promoter, Managing Director

Associated with Company since 1986Chemical Engineer, PGDM from IIM, Calcutta



Mr. Natarajan K. Krishnan Executive Director, Chief Operating Officer

Associated with Company since 1993
CWA, Advanced Management Program from Harvard Business School



Mr. Kasargod Ganesh Kamath Executive Director (Finance), Chief Financial Officer

Associated with Company since 2004
Qualified CS, CWA and LL.B, over 20 years of experience



Mr. Vaijanath Kulkarni Non-Executive Director

Associated with Company since 1995
Chemical Engineer
Currently, MD of Galaxy Chemicals (Egypt) S.A.E







Mr. Shekhar Ravindranath Warriar Chairman, Non-Executive Independent Director

Associated with Company since 2007
More than 30 years with Unilever, India in various capacities



Mr. Gopalkrishnan Ramakrishnan Promoter, Non-Executive Director

•Associated with Company since 1986 •Qualified CA and CS



Mr. Shashikant R. Shanbhag Promoter, Non-Executive Director

Associated with Company since1986Qualified CA



Mr. Subodh S. Nadkarni Non-Executive Independent Director

Associated with Company since
2002, 30 years+ experience
Qualified CA and CS, prior
associations with Godrej and Sulzer



Mr. Melarkode G. Parameswaran Non-Executive Independent Director

Associated with Company since 2005
 Chemical Engineer from IIT Madras;
 PGDM from IIM Calcutta; PhD from
 Mumbai University



Ms. Nandita Gurjar Non-Executive Independent Director

•Associated with Company since 2015 •Over 20 years of experience in the field of IT and Human Resource



The 4 Cs: Our Core Strength





Transparent & Open, Respect & Value People, Dreaming & Envisioning, Conducting Business with Integrity



COMPETENCE

Talented Team which proactively meets Complex & Changing Business Needs



Adhering to Global Quality Standards, Supplying Customers Globally, Agile & Nimble Footedness



COMFORT

Respecting our Commitments, Consistent Performance over the years of Timely Delivery & Quality Consistency






Growth Strategy


Personal & Home Care: High Entry Barrier Businesses















Financial Performance






... through Robust Risk Management Practices



Volume: FY21 Highlights (YoY)






Responsible Care®

FY21 Highlights (YoY)


Responsible Care®





Our Performance Highlights







Responsible Care


^Includes other Income






Cash Flow from Operating Activities (Rs in Crs)





Return on Equity (%)







Consolidated Balance Sheet



Particulars (Rs. In Crores)	Mar'21	Mar'20
ASSETS		
Property, Plant and Equipment	591.7	623.9
Right-of-use assets	111.9	115.7
Capital work-in-progress	124.0	66.0
Goodwill	2.7	2.8
Other Intangible Assets	5.7	5.5
Financial Assets		
(i) Loans	0.3	7.7
(ii) Other financial assets	8.9	0.8
Deferred Tax Assets (Net)	0.7	0.1
Income Tax Assets (Net)	11.2	15.9
Other Non-current tax assets	35.0	38.7
Total Non-Current Assets	891.8	877.0
Current Assets		
Inventories	427.8	325.0
Financial Assets		
(i) Investments	43.5	5.8
(ii) Trade receivables	468.9	439.4
(iii) Cash and cash equivalents	81.5	47.7
(iv) Bank Balances other than cash and cash equivalents	29.9	6.5
(v) Loans	0.3	0.4
(vi) Other Financial Assets	5.9	6.8
Other Current Assets	99.9	103.3
Total Current Assets	1,157.7	935.0

Particulars (Rs. In Crores)	Mar'21	Mar'20
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	1,266.0	1,032.3
Total Shareholders Fund	1,301.4	1,067.8
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	77.4	116.6
(ii) Lease Liabilities	16.9	19.7
(iii) Other Financial Liabilities	0.4	0.3
Provisions	10.1	13.8
Deferred Tax Liabilities (Net)	23.3	24.1
Other non-current liabilities	0.0	0.4
Total Non-Current Liabilities	128.0	175.0
Current Liabilities		
Financial Liabilities		
(i) Borrowings	190.6	203.0
(ii) Trade Payables	377.0	273.1
(iii) Lease Liabilities	4.4	3.9
(iv) Other Financial Liabilities	5.4	62.5
Other Current Liabilities	33.0	17.7
Provisions	8.6	3.9
Current Tax Liabilities (Net)	1.2	5.2
Total Current Liabilities	620.1	569.2
TOTAL EQUITY & LIABILITIES	2,049.5	1,812.0



Consolidated Cash Flow



	Full Year ended		
Particulars (Rs. In Crores)	Mar'21	Mar'20	
Cash Flow From Operating Activities :			
Profit After Tax	302.1	230.4	
Operating Profit before working Capital changes	454.2	373.0	
Net cash flows generated from/(used) in Operating Activities (A)	365.1	315.9	
Net cash flows generated from/(used) in Investing Activities (B)	(164.7)	(150.8)	
Net cash flows generated from/(used) in Financing Activities (C)	(165.0)	(143.8)	
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	35.4	21.3	
Opening cash and cash equivalents	47.7	25.0	
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	(1.6)	1.4	
Closing cash and cash equivalents	81.5	47.7	



Standalone Balance Sheet



Particulars (Rs. In Crores)	Mar'21	Mar'20
ASSETS		
Property, Plant and Equipment	358.5	369.6
Right-of-use assets	99.2	102.4
Capital work-in-progress	116.2	61.4
Goodwill		
Other Intangible Assets	5.6	5.3
Financial Assets		
(i) Investments	216.7	218.2
(ii) Loans	0.3	5.6
(iii) Other financial assets	5.6	0.0
Deferred Tax Assets (Net)		
Income Tax Assets (Net)	8.0	8.0
Other Non-current tax assets	28.6	36.9
Total Non-Current Assets	838.7	807.3
Current Assets		
Inventories	270.2	202.1
Financial Assets		
(i) Trade receivables	339.6	274.1
(ii) Cash and cash equivalents	11.9	16.9
(iii) Bank Balances other than cash and cash equivalents	12.9	0.7
(iv) Loans	0.3	0.3
(v) Other Financial Assets	6.0	9.5
Other Current Assets	78.1	78.1
Total Current Assets	718.9	581.8
TOTAL ASSETS	1,557.6	1,389.1

Particulars (Rs. In Crores)	Mar'21	Mar'20
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	981.4	854.4
Total Shareholders Fund	1,016.8	889.8
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	53.0	83.0
(ii) Lease Liabilities	4.8	7.1
(iii) Other Financial Liabilities	0.4	0.3
Provisions	10.1	13.8
Deferred Tax Liabilities (Net)	29.3	30.5
Other non-current liabilities	0.0	0.4
Total Non-Current Liabilities	97.5	135.1
Current Liabilities		
Financial Liabilities		
(i) Borrowings	110.8	58.0
(ii) Trade Payables	306.5	226.9
(iii) Lease Liabilities	2.7	2.3
(iv) Other Financial Liabilities	4.0	56.6
Other Current Liabilities	12.8	11.5
Provisions	5.2	3.6
Current Tax Liabilities (Net)	1.2	5.2
Total Current Liabilities	443.2	364.1
TOTAL EQUITY & LIABILITIES	1,557.6	1,389.1



Standalone Cash Flow



	Full Year ended		
Particulars (Rs. In Crores)	Mar'21	Mar'20	
Cash Flow From Operating Activities :			
Profit After Tax	177.9	182.2	
Operating Profit before working Capital changes	296.5	284.0	
Net cash flows generated from/(used) in Operating Activities (A)	183.7	212.5	
Net cash flows generated from/(used) in Investing Activities (B)	(104.5)	(37.9)	
Net cash flows generated from/(used) in Financing Activities (C)	(84.2)	(160.7)	
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	(5.0)	13.9	
Opening cash and cash equivalents	16.9	3.9	
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	0.0	(0.9)	
Closing cash and cash equivalents	11.9	16.9	





Thank You

Company :



CIN No: L39877MH1986PLC039877

Mr. Paritosh Srivastava Email: <u>Paritosh.Srivastava@galaxysurfactants.com</u>

www.galaxysurfactants.com

Investor Relations Advisors :



CIN - U74140MH2010PTC204285

Mr. Rahul Agarwal / Mr. Vijay Goel rahul.agarwal@sgapl.net / vijay.goel@sgapl.net

+91 98214 38864 / +91 99201 24357

www.sgapl.net

